Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
Key Highlights
- ➤Entera will present EB613 Phase 3 osteoporosis study design at ASBMR 2026
- ➤EB613 Phase 3 trial planned as randomized, double-blind, placebo-controlled study
- ➤Phase 2 161-patient study met all biomarker and BMD endpoints
- ➤EB613 produced rapid bone-formation increases and BMD gains without significant safety concerns
Expert Statements
Felicia Cosman, Professor of Medicine at Columbia University
“EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design”
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.
The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design,” has been accepted as a late-breaking poster presentation (Presentation Number: Sun-522) during Late Breaking Poster Session II on Sunday, October 11, 2026. Led by Dr. Felicia Cosman, Professor of Medicine at Columbia University and an internationally recognized osteoporosis authority, the presentation will outline the study design and clinical methodology for Entera’s planned single, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating EB613 in postmenopausal women with osteoporosis.
Get started
Create a free account to read the full story.